Lambda Biologics GmbH, located in the Leipzig Bio Cluster in Germany and led by CEO André Gerth, operates a biohealth testing platform. The company is growing as both a testing platform and a hub for knowledge and research, focusing not only on accurate test results but also on streamlining and advancing researchers’ work processes.
Lambda Biologics received a public grant of the Free State of Saxony (Germany) in October to support the development of regenerative medicine and advanced therapy medicinal products (ATMPs). ORGANOIDSCIENCES (CEO Jongman Yoo) was selected among Lambda Biologics’ various corporate partners to jointly drive this development forward.
ORGANOIDSCIENCES received ATMP certification for ATORM-C in 2023 from the EMA (European Medicines Agency). ATMP, which includes gene therapies, cell therapies, and tissue-engineered products, represents an innovative alternative that transcends the limitations of existing pharmaceuticals. Germany, with its world-class medical system and ATMP regulatory framework, is an ideal location for developing and commercializing these therapies.
Germany’s supportive environment and regulatory framework for ATMPs provide excellent conditions for biotech company growth. For example, the Hospital Exemption pathway allows for faster treatment delivery to patients compared to standard procedures. Additionally, collaboration between academia, industry, and regulatory authorities provides substantial resources, leading to large-scale ATMP clinical trials across Europe.
Furthermore, European public funding support enables companies to receive continued funding and equity capital of over €15 million after the initial phase. Through this support, Lambda Biologics plans to expand its research and development of treatments across Europe, not just in Germany, in collaboration with ORGANOIDSCIENCES.
Media Contact
Company Name: Lambda Biologics
Contact Person: Jeongsun Chae
Email: Send Email
Country: Germany
Website: https://afs.lambda-bio.com/